# Silymarin in NAFLD

> **NCT02973295** · PHASE4 · WITHDRAWN · sponsor: **University Hospital Rijeka**

## Conditions studied

- Non-Alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Silymarin
- **OTHER:** Placebo Oral Capsule

## Key facts

- **NCT ID:** NCT02973295
- **Lead sponsor:** University Hospital Rijeka
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-09-20
- **Primary completion:** 2020-12
- **Final completion:** 2021-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor withdrawn their agreement
- **Last updated:** 2020-11-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02973295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02973295, "Silymarin in NAFLD". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02973295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*